A genetic profiling guideline to support diagnosis and clinical management of lymphomas

被引:0
作者
Margarita Sánchez-Beato
Miriam Méndez
María Guirado
Lucía Pedrosa
Silvia Sequero
Natalia Yanguas-Casás
Luis de la Cruz-Merino
Laura Gálvez
Marta Llanos
Juan Fernando García
Mariano Provencio
机构
[1] Hospital Universitario Puerta de Hierro-Majadahonda,Servicio de Oncología Médica, Grupo de Investigación en Linfomas
[2] IDIPHISA,Servicio de Oncología Médica
[3] Grupo Oncológico para el Tratamiento y Estudio de los Linfomas-GOTEL,Servicio de Oncología Médica
[4] Hospital Universitario Puerta de Hierro-Majadahonda,Servicio de Oncología Médica
[5] IDIPHISA,Servicio de Oncología Médica, Facultad de Medicina
[6] Hospital General Universitario de Elche,Unidad de Gestión Clínica Intercentros de Oncología Médica
[7] Hospital Universitario San Cecilio,Servicio de Oncología Médica
[8] Hospital Universitario Virgen Macarena,Servicio de Anatomía Patológica
[9] Universidad de Sevilla,Servicio de Oncología Médica, Departamento de Medicina, Facultad de Medicina
[10] Instituto de Biomedicina de Sevilla (IBID)/CSIC,undefined
[11] Hospitales Universitarios Regional y Virgen de la Victoria,undefined
[12] Hospital Universitario de Canarias,undefined
[13] Hospital MD Anderson Cancer Center,undefined
[14] Hospital Universitario Puerta de Hierro-Majadahonda,undefined
[15] Universidad Autónoma de Madrid,undefined
[16] IDIPHISA,undefined
来源
Clinical and Translational Oncology | 2024年 / 26卷
关键词
Lymphoma; Next-generation sequencing; Diagnosis; Prognosis;
D O I
暂无
中图分类号
学科分类号
摘要
The new lymphoma classifications (International Consensus Classification of Mature Lymphoid Neoplasms, and 5th World Health Organization Classification of Lymphoid Neoplasms) include genetics as an integral part of lymphoma diagnosis, allowing better lymphoma subclassification, patient risk stratification, and prediction of treatment response. Lymphomas are characterized by very few recurrent and disease-specific mutations, and most entities have a heterogenous genetic landscape with a long tail of recurrently mutated genes. Most of these occur at low frequencies, reflecting the clinical heterogeneity of lymphomas. Multiple studies have identified genetic markers that improve diagnostics and prognostication, and next-generation sequencing is becoming an essential tool in the clinical laboratory. This review provides a “next-generation sequencing” guide for lymphomas. It discusses the genetic alterations of the most frequent mature lymphoma entities with diagnostic, prognostic, and predictive potential and proposes targeted sequencing panels to detect mutations and copy-number alterations for B- and NK/T-cell lymphomas.
引用
收藏
页码:1043 / 1062
页数:19
相关论文
共 871 条
  • [1] Campo E(2022)The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the clinical advisory committee Blood 140 1229-1253
  • [2] Jaffe ES(2022)The 5th of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms Leukemia 36 1720-1748
  • [3] Cook JR(1995)Chronic lymphocytic leukemia N Engl J Med 333 1052-1057
  • [4] Quintanilla-Martinez L(2021)Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures Am J Hematol 96 1679-1705
  • [5] Swerdlow SH(2000)Genomic aberrations and survival in chronic lymphocytic leukemia N Engl J Med 343 1910-1916
  • [6] Anderson KC(2018)The role of the genetic abnormalities, epigenetic and microRNA in the prognosis of chronic lymphocytic leukemia Exp Oncol 40 261-267
  • [7] Alaggio R(2016)A high proportion of cells carrying trisomy 12 is associated with a worse outcome in patients with chronic lymphocytic leukemia Hematol Oncol 34 84-92
  • [8] Amador C(1997)11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis Blood 89 2516-2522
  • [9] Anagnostopoulos I(2019)17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia J Immunother Cancer 7 22-1418
  • [10] Attygalle AD(2016)Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study Lancet Oncol 17 1409-1980